Cancer prevalence in the UK: results from the EUROPREVAL study

被引:61
作者
Forman, D
Stockton, D
Moller, H
Quinn, M
Babb, P
De Angelis, R
Micheli, A
机构
[1] No & Yorkshire Canc Registry & Informat Serv, Leeds, W Yorkshire, England
[2] Univ Leeds, Leeds, W Yorkshire, England
[3] Natl Hlth Serv Scotland, Scottish Canc Intelligence Unit, Informat & Stat Div, Edinburgh, Midlothian, Scotland
[4] Kings Coll London, Thames Canc Registry, London WC2R 2LS, England
[5] London Sch Hyg & Trop Med, London WC1, England
[6] Off Natl Stat, Natl Canc Intelligence Ctr, London, England
[7] Ist Super Sanita, I-00161 Rome, Italy
[8] Ist Nazl Studio & Cura Tumori, I-20133 Milan, Italy
关键词
cancer; cancer registry; prevalence; UK;
D O I
10.1093/annonc/mdg169
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Cancer incidence, mortality and survival statistics for the UK are routinely available however, data on prevalence, which is generally regarded as an important measure for health planning and resource allocation, are relatively scarce. Materials and methods: Eight cancer registries in the UK, covering more than half the population, provided data based on >1.5 million cases of cancer. Total prevalence was calculated using methods developed for the EUROPREVAL study, based on modelling incidence and survival trends. The prevalence of cancers of the stomach, colon, rectum, lung, breast(in females),cervix uteri,corpus uteri and prostate, melanoma of skin, Hodgkin's disease, leukaemia and all malignant neoplasms combined, was estimated for the UK for the end of 1992, Results: Overall, similar to1.5% of males and 2.5% of females in the UK population at the end of 1992 were living with a diagnosis of cancer. These proportions increased steeply with age, with similar to7.5% (7.3% and 7.9%, in males and females, respectively) of people aged 65 years living with a diagnosis of cancer. Of the individual cancers, by far the highest prevalence (almost 1%) was seen for breast cancer in females, more than one in three of all living female cancer patients had been diagnosed with breast cancer. For males, around half of prevalent cases had been diagnosed >5 years previously and 30% >10 years previously; for females, these figures were both higher, at similar to60% and 40%, respectively. Conclusions: The estimates of prevalence presented here comprise: recently diagnosed patients in need of treatment and monitoring; long-term survivors, some of whom will nevertheless eventually die from the cancer, while others may be cured of the disease; and patients in the terminal phase who are dying from the cancer. Further work should attempt to identify the proportions of patients, in the different phases of care in order to optimise the use of prevalence estimates in health care planning.
引用
收藏
页码:648 / 654
页数:7
相关论文
共 18 条
[1]  
BOOTH H, 2002, SERIES MBI, V29
[2]   Obtaining long-term disease specific costs of care - Application to Medicare enrollees diagnosed with colorectal cancer [J].
Brown, ML ;
Riley, GF ;
Potosky, AL ;
Etzioni, RD .
MEDICAL CARE, 1999, 37 (12) :1249-1259
[3]   Measuring cancer prevalence in europe: the EUROPREVAL project [J].
Capocaccia, R ;
Colonna, M ;
Corazziari, I ;
De Angelis, R ;
Francisci, S ;
Micheli, A ;
Mugno, E .
ANNALS OF ONCOLOGY, 2002, 13 (06) :831-839
[4]  
Capocaccia R, 1997, STAT MED, V16, P425, DOI 10.1002/(SICI)1097-0258(19970228)16:4<425::AID-SIM414>3.0.CO
[5]  
2-Z
[6]  
CAPOCACCIA R, 1999, IARC SCI PUBL, V151, P1
[7]  
COLEMAN MP, 2000, HLTH STAT Q, V6, P54
[8]  
COLEMAN MP, 1999, STUDIES MED POPULATI, V61
[9]  
Fireman BH, 1997, HEALTH CARE FINANC R, V18, P51
[10]  
Krogh V, 1996, TUMORI, V82, P287